Skip to main content

Advertisement

SpringerLink
Log in

Is fibromyalgia a distinct clinical syndrome?

  • Published:
Current Review of Pain Aims and scope Submit manuscript

Abstract

The validity of the fibromyalgia syndrome (FMS) as a distinct clinical entity has been challenged for several reasons. Many skeptics express concern about the subjective nature of chronic pain, the subjectivity of the tender point (TeP) examination, the lack of a gold standard laboratory test, and the absence of a clear pathogenic mechanism by which to define FMS. Another expressed concern has been the relative nature of the pain-distress relationship in the rheumatology clinic. The apparently continuous relationship between TePs and somatic distress across a variety of clinical disorders is said to argue against FMS as a separate clinical disorder. The most aggressive challenges of the FMS concept have been from legal defenses of insurance carriers motivated by economic concerns. Other forms of critique have presented as psychiatric dogma, uninformed posturing, suspicion of malingering, ignorance of nociceptive physiology, and occasionally have resulted from honest misunderstanding. It is not likely that a few paragraphs of data and logic will cause an unbeliever to change an ingrained opinion. Therefore, this review describes the clinical manifestations of FMS, responds to some of the theoretic arguments against it, and discusses some possible pathophysiologic mechanisms by which FMS may develop and persist as a unique syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wolfe F, Smythe HA, Yunus MB, et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990, 33:160–172.

    Article  CAS  PubMed  Google Scholar 

  2. Alarcon GS, Bradley LA, eds: Advances in fibromyalgia. Am J Med Sci 1998, 315:346–404.

    Article  Google Scholar 

  3. Wolfe F, Anderson J, Harkness D, et al.: A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997, 40:1560–1570. Examines the natural history of fibromyalgia in a large number of patients over more than 7 years and establishes the cost of this disorder to the United States economy as of the year 1994.

    Article  CAS  PubMed  Google Scholar 

  4. Henriksson C, Gundmark I, Bengtsson A, Ek AC: Living with fibromyalgia. Consequences for everyday life. Clin J Pain 1992, 8:138–144.

    Article  CAS  PubMed  Google Scholar 

  5. Henriksson C, Burckhardt C: Impact of fibromyalgia on everyday life: a study of women in the USA and Sweden. Disabil Rehabil 1996, 18:241–248.

    Article  CAS  PubMed  Google Scholar 

  6. Russell IJ, Vipraio GA, Morgan WW, Bowden CL: Is there a metabolic basis for the fibrositis syndrome? Am J Med 1986, 81:50–56.

    Article  CAS  PubMed  Google Scholar 

  7. Tunks E, McCain GA, Hart LE, et al.: The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. J Rheumatol 1995, 22:944–952.

    CAS  PubMed  Google Scholar 

  8. Campbell SM, Clark S, Tindall EA, et al.: Clinical characteristics of fibrositis. I. A “blinded,” controlled study of symptoms and tender points. Arthritis Rheum 1983, 26:817–824.

    Article  CAS  PubMed  Google Scholar 

  9. Simms RW, Goldenberg DL, Felson DT, Mason JH: Tenderness in 75 anatomic sites. Distinguishing fibromyalgia patients from controls. Arthritis Rheum 1988, 31:182–187.

    Article  CAS  PubMed  Google Scholar 

  10. Russell IJ: The reliability of algometry in the assessment of patients with fibromyalgia syndrome. J Musculoske Pain 1998, 6:139–152.

    Article  Google Scholar 

  11. Wolfe F: The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 1997, 56:268–271.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Wolfe F, Ross K, Anderson J, et al.: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19–28.

    Article  CAS  PubMed  Google Scholar 

  13. Wolfe F, Russell IJ, Vipraio GA, et al.: Serotonin levels, pain threshold, and FM. J Rheumatol 1997, 24:555–559.

    CAS  PubMed  Google Scholar 

  14. Wolfe F, Ross K, Anderson J, Russell IJ: Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995, 22:151–156.

    CAS  PubMed  Google Scholar 

  15. Russell IJ: Is fibromyalgia a distinct clinical entity? The clinical investigator’s evidence. Ballieres Clin Rheumatol 1999, 13:445–454.

    Article  CAS  Google Scholar 

  16. McCance DR, Hanson RL, Charles MA, et al.: Comparison of tests for glycated hemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994, 308:1323–1328.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Paik M: A graphic representation of a three-way contingency table: Simpson’s paradox and correlation. Am Statistician 1985, 39:53–54.

    Google Scholar 

  18. Crofford LJ, Pillemer SR, Kalogeras KT, et al.: Hypothalamicpituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994, 37:1583–1592.

    Article  CAS  PubMed  Google Scholar 

  19. Bennett RM, Clark SR, Burckhardt CS, Cook D: IGF-1 assays and other GH tests in 500 fibromyalgia patients [abstract]. J Musculoske Pain 1995, 3(suppl_1):109.

    Google Scholar 

  20. Bennett RM, Clark SC, Walczyk J: A randomized, doubleblind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998, 104:227–231.

    Article  CAS  PubMed  Google Scholar 

  21. Bou-Holaigah I, Calkins H, Flynn JA, et al.: Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol 1997, 15:239–246.

    CAS  PubMed  Google Scholar 

  22. Martinez-Lavin M, Hermosillo AG, Mendoza C, et al.: Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997, 24:714–718.

    CAS  PubMed  Google Scholar 

  23. Clauw DJ, Radulovic D, Heshmat Y, Barbey JT: Heart rate variability as a measure of autonomic function in patients with fibromyalgia (FM) and chronic fatigue syndrome (CFS) [abstract]. J Musculoske Pain 1995, 3(suppl 1):78.

    Google Scholar 

  24. Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME: Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 1998, 41:1966–1971. Shows that at least some patients with FMS exhibit a diurnal dysfunction in their autonomic nervous system control of heart rate regulation.

    Article  CAS  PubMed  Google Scholar 

  25. Bonica JJ: Definitions and taxonomy of pain. In The Management of Pain, vol 1, edn 2. Edited by Bonica JJ et al. Philadelphia: Lea & Febiger; 1990:18–27.

    Google Scholar 

  26. Malmberg AB, Yaksh TL: Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992, 257:1276–1279.

    Article  CAS  PubMed  Google Scholar 

  27. Russell IJ: Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoske Pain 1996, 1:61–92.

    Article  Google Scholar 

  28. Hoheisel U, Mense S, Ratkai M: Effects of spinal cord superfusion with substance P on the excitability of rat dorsal horn neurons processing input from deep tissues. J Musculoske Pain 1995, 3:23–43.

    Article  Google Scholar 

  29. Vaeroy H, Helle R, Forre O, et al.: Elevated CSF levels of substance P and high incidence of Raynaud’s phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21–26.

    Article  CAS  PubMed  Google Scholar 

  30. Russell IJ, Orr MD, Littman B, et al.: Elevated cerebrospinal levels of substance P patients with fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593–1601.

    Article  CAS  PubMed  Google Scholar 

  31. Welin M, Bragee B, Nyberg F, Kristiansson M: Elevated substance P levels are contrasted by a decrease in metenkephalin-arg-Phe levels in CSF from fibromyalgia patients [abstract]. J Musculoske Pain 1995, 3(suppl 1):4.

    Google Scholar 

  32. Alberts KR, Bradley LA, Mountz JM, et al.: Regional cerebral blood flow (Rcbf) in the caudate nucleus and thalamus of fibromyalgia (FM) patients is associated with the cerebrospinal fluid (CSF) levels of substance P (SP) [abstract]. In 8th World Congress on Pain, Aug 17–22. Seattle, WA: IASP Press; 1996:445.

    Google Scholar 

  33. Russell IJ, Fletcher EM, Vipraio GA, et al.: Cerebrospinal fluid [CSF] substance P [SP] in fibromyalgia: changes in CSF SP over time parallel changes in clinical activity [abstract]. J Musculoske Pain 1998, 6(suppl 2):77.

    Google Scholar 

  34. Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor (NGF) in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564–1569.

    CAS  PubMed  Google Scholar 

  35. Nyberg F, LeGreves P, Sundqvist C, Terenius L: Characterization of substance P(1-7) and (1-8) generating enzyme in human cerebrospinal fluid. Biochem Biophys Res Commun 1984, 125:244–250.

    Article  CAS  PubMed  Google Scholar 

  36. Yukhananov RYU, Larson AA: An N-terminal fragment of substance P, Substance P(1-7), down-regulates neurokinin-1 binding in the mouse spinal cord. Neurosci Lett 1994, 178:163–166.

    Article  CAS  PubMed  Google Scholar 

  37. Skilling SR, Smullin DH, Larson AA: Differential effects of C- and N-terminal substance P metabolites on the release of amino acid neurotransmitters from the spinal cord: potential role in nociception. J Neurosci 1990, 10:1309–1318.

    CAS  PubMed  Google Scholar 

  38. Russell IJ, Orr MD, Michalek JE, et al.: Substance P (SP), SP endopeptidase activity, and SP N-terminal peptide fragment (SP1-7) in fibromyalgia syndrome cerebrospinal fluid [abstract]. J Musculoske Pain 1995, 3(suppl 1):5.

    Google Scholar 

  39. Schwarz MJ, Spath M, Müller-Bardorff H, et al.: Relationship of substance P, 5-hydroxyindole acetic acid, and tryptophan in serum of fibromyalgia patients. Neurosci Lett 1999, 259:196–198.

    Article  CAS  PubMed  Google Scholar 

  40. Russell IJ, Michalek JE, Vipraio GA, et al.: Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992, 19:104–109.

    CAS  PubMed  Google Scholar 

  41. Stratz T, Samborski W, Hrycaj P, et al.: Serotonin concentration in serum of patients with generalized tendomyopathy (fibromyalgia) and chronic polyarthritis [in German]. Med Klin 1993, 88:458–462.

    CAS  Google Scholar 

  42. Hrycaj P, Stratz T, Muller W: Platelet 3H-imipramine uptake receptor density and serum serotonin in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1993, 20:1986–1987.

    CAS  PubMed  Google Scholar 

  43. Russell IJ, Vipraio GA: Serotonin (5HT) in serum and platelets (PLT) from fibromyalgia patients (FS) and normal controls (NC) [abstract]. Arthritis Rheum 1994, 37(suppl):S214.

    Article  Google Scholar 

  44. Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550–556.

    Article  CAS  PubMed  Google Scholar 

  45. Russell IJ, Vipraio GA, Acworth I: Abnormalities in the central nervous system [CNS] metabolism of tryptophan [TRY] to 3-hydroxy kynurenine [OHKY] in fibromyalgia syndrome [FS] [abstract]. Arthritis Rheum 1993, 36:S222.

    Article  Google Scholar 

  46. Kang Y-K, Russell IJ, Vipraio GA, Acworth IN: Low urinary 5-hydroxyindole acetic acid in fibromyalgia syndrome: evidence in support of a serotonin-deficiency pathogenesis. Myalgia 1998, 1:14–21.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Clinical Immunology, The University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7868, 78229, San Antonio, TX, USA

    Chi-lun Rau MD & I. Jon Russell MD, PhD

Authors
  1. Chi-lun Rau MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Jon Russell MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rau, Cl., Russell, I.J. Is fibromyalgia a distinct clinical syndrome?. Current Review of Pain 4, 287–294 (2000). https://doi.org/10.1007/s11916-000-0105-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-000-0105-4

Keywords

Search

Navigation